Chief Operating Officer Of Dyne Therapeutics Sold 71% Of Their Shares
Chief Operating Officer Of Dyne Therapeutics Sold 71% Of Their Shares
We wouldn't blame Dyne Therapeutics, Inc. (NASDAQ:DYN) shareholders if they were a little worried about the fact that Susanna High, the Chief Operating Officer recently netted about US$725k selling shares at an average price of US$26.67. Probably the most concerning element of the whole transaction is that the disposal amounted to 71% of their entire holding.
如果達因療法公司(納斯達克股票代碼:DYN)股東對首席運營官蘇珊娜·海最近以26.67美元的平均價格淨出售股票約72.5萬美元感到擔憂,我們就不會責怪他們。整個交易中最令人擔憂的因素可能是處置佔其全部持股量的71%。
The Last 12 Months Of Insider Transactions At Dyne Therapeutics
Dyne Therapeutics 過去 12 個月的內幕交易
Notably, that recent sale by Susanna High is the biggest insider sale of Dyne Therapeutics shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of US$26.68. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.
值得注意的是,蘇珊娜·海最近的一次出售是我們去年對達因療法股票的最大一次內幕出售。因此,我們知道一位內部人士以目前的26.68美元左右的股價出售了股票。我們通常不喜歡看到內幕銷售,但是銷售價格越低,我們就越擔心。鑑於此次出售是以當前價格進行的,這使我們有點謹慎,但並不是主要問題。
Insiders in Dyne Therapeutics didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
去年,達因療法的內部人士沒有購買任何股票。您可以看到下圖所示的去年的內幕交易(公司和個人)。通過點擊下面的圖表,你可以看到每筆內幕交易的確切細節!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240315/0-b06e22bfae6f00cd657afb971bb15e89-0-6d2ae966f0f6113d9625a1aae0e3a34b.png/big)
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果你像我一樣,那麼你不會想錯過這份業內人士正在收購的成長型公司的免費名單。
Does Dyne Therapeutics Boast High Insider Ownership?
Dyne Therapeutics是否擁有很高的內部所有權?
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 0.3% of Dyne Therapeutics shares, worth about US$7.3m, according to our data. We do generally prefer see higher levels of insider ownership.
對於普通股股東來說,值得檢查一下公司內部人士持有多少股票。通常,內部人士的所有權越高,內部人士長期建立公司的可能性就越大。根據我們的數據,內部人士擁有達因療法0.3%的股份,價值約730萬美元。我們通常更願意看到更高的內部所有權水平。
So What Does This Data Suggest About Dyne Therapeutics Insiders?
那麼,這些數據對達因療法內部人士有何啓示呢?
Insiders sold Dyne Therapeutics shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 5 warning signs for Dyne Therapeutics you should be aware of, and 1 of them makes us a bit uncomfortable.
業內人士最近出售了達因療法的股票,但他們沒有購買任何股票。展望過去的十二個月,我們的數據並未顯示任何內幕買盤。內部人士擁有該公司的股票相對較少,當你考慮銷售情況時,我們對這隻股票並不特別興奮。因此,至少可以說,我們並不急於購買。因此,這些內幕交易可以幫助我們建立有關股票的論點,但也值得了解這家公司面臨的風險。一個很好的例子:我們發現了你應該注意的達因療法的5個警告信號,其中一個讓我們有點不舒服。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。